Supplementary Figure S8 from Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus

Supplementary Figure S8. Tissue distribution of DBPR728 and its active moiety 6K465. LC-MS/MS quantification for the concentrations of DBPR728 and 6K465 in tissues (plasma, heart, aorta, liver, lung and kidney) of ICR mice (n = 7) after 24 hr of taking one 300 mpk dose of DBPR728. Errors are mean ± SD.